Zidovudine-associated mitochondriopathy: Three possible observations in Abidjan, Côte d'Ivoire;Mitochondriopathie associée à la zidovudine. A propos de 3 cas possibles à Abidjan, Côte d'Ivoire

Bulletin de la Societe de Pathologie Exotique

Volumn 97, Issue 4, 2004, Pages 253-256

  Elenga, N ^a,e   Msellati, P ^b   Fassinou, P ^c   Viho, I ^a   Dabis, F ^d  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE YOPOUGON   (Côte d’Ivoire)

^d INSERM   (France)

^e HÔPITAL DEBROUSSE   (France)

Author keywords

Abidjan; C te d'Ivoire; HIV; Mitochondrial dysfunction; Mother to child transmission; Sub Saharan Africa; Toxicity; Zidovudine

Indexed keywords

ANTIRETROVIRUS AGENT; VALPROIC ACID; ZIDOVUDINE;

AFRICA; ANAMNESIS; ANTHROPOMETRIC ABNORMALITY; ANTHROPOMETRY; ARTICLE; CASE REPORT; CLINICAL OBSERVATION; COHORT ANALYSIS; DETERIORATION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE TRANSMISSION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FEMALE; GRAND MAL SEIZURE; GROWTH DISORDER; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MEDICAL EXAMINATION; MONOTHERAPY; NEUROLOGIC DISEASE; PREGNANCY; PSYCHOMOTOR DEVELOPMENT; PSYCHOMOTOR DISORDER; SIDE EFFECT; SYMPTOM;

ADULT; ANEMIA, HYPOCHROMIC; ANTI-HIV AGENTS; COHORT STUDIES; COMORBIDITY; COTE D'IVOIRE; EPILEPSY, GENERALIZED; FAILURE TO THRIVE; FEMALE; FETUS; GROWTH DISORDERS; HIV INFECTIONS; HUMANS; INFANT; MALE; MITOCHONDRIA; MUSCLE HYPOTONIA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL EXPOSURE DELAYED EFFECTS; PROTEIN-ENERGY MALNUTRITION; PSYCHOMOTOR DISORDERS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; ZIDOVUDINE;

EID: 10344230941     PISSN: 00379085     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. BHADRAKOM C, SIMONDS RJ, MEI JV ASAVAPIRIYANONT S, SANGTAWEESIN V et al. - Oral zidovudine during labor to prevent perinatal HIV transmission, Bangkok: tolerance and zidovudine concentration in cord blood. AIDS, 2000, 14, 509-519.
2. BLANCHE S - Mitochondrial toxicity resulting from the treatment of pregnant women and infants. Abstract No 48, CROL, 2004.
3. BLANCHE S, TARDIEU M, RUSTIN P, SLAMA A, BARRET B, et al. - Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues, Lancet, 1999, 354, 1084-1089.
4. BRINKMAN K, TER HOFSTEDE HJM, BURGER MD, SMEITING JAM & KOOPMANS PP - Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS, 1998, 12, 1735-1744.
5. CULNANE M, FOWLER MG, LEE SS, MCSHERRY G, BRADY M et al. - Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women, JAMA, 1999, 281, 151-157.
6. DABIS F, MSELLATI P, MEDA N, WELFFENS-EKRA C, YOU B et al. - Six month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet, 1999, 353, 786-792.
7. DOMINGUEZ K, BERTOLLI J, FOWLER M, PETERS V, ORTIZ I et al. - Lack of definitive severe mitochondrial signs and symptoms among deceased HIV-uninfected and HIV-indeterminate children < or = 5 years of age, Pediatric Spectrum of HIV Disease project (PSD), USA. Ann NY Acad Sci, 2000, 918, 236-246.
8. GERSCHENSON M, ERHART SW, PAIK CY, ST CLAIRE MC, NAGASHIMA K et al. - Fetal mitochondrial heart and skeletal muscle damage in Erythrocebus patas monkeys exposed in utero to 3′azido-3′-deoxythymidine. AIDS Res Hum Retroviruses, 2000, 16, 635-644.
9. HANSON IC, ANTONELLI TA, SPERLING RS, OLESKE JM, COOPER E et al. - Lack of tumors in infants with perinatal HIV-1 exposure and fetal / neonatal exposure to zidovudine. J Acquir Immune Defic Syndr, 1999, 20, 463-467.
10. KANSHANA S, THEWANDA D, TEERARATKUL A, LIMPAKARNJANARAT K, AMORNWICHET P et al. - Implementing short-course zidovudine to reduce mother-infant HIV transmission in a large pilot program in Thailand. AIDS, 2000, 14, 1617-1623.
11. LANGE J, STELLATO R & BRINKMAN K - Review of neurological adverse events in relation to mitochondrial dysfunction in the prevention of mother to child transmission of HIV: PETRA Study. Second conference on global strategies for the prevention of VIH transmission from mothers to infants, Montreal, Canada: September 1999. Abstract 250.
12. LIPSHULTZ, SE, EASLEY, KA, ORAV, EJ, KAPLAN S, STARC TJ et al. - Absence of cardiac toxicity of zidovudine in infants. N Engl J Med, 2000, 343, 759-766.
13. MOFENSON LM - Perinatal exposure to zidovudine. Benefits and Risks. New Engl J Med, 2000, 343, 759-766.
14. MORRIS AA & CARR A - HIV nucleoside analogues: new adverse effects on mitochondria? Lancet, 1999, 354, 1046-1047.
15. MSELLATI P, HINGST G, KABA F, VIHO I, WELFFENS-EKRA C & DABIS F - Operational issues in preventing mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire, 1988-99. Bull World Health Organ, 2001, 79, 641-647.
16. ORG MONO SANTÉ - Nouvelles données concernant la prévention de la transmission du VIH de la mère à l'enfant et leurs implications politiques. Consultation technique OMS au nom de l'Equipe Spéciale InterAgences ONUSIDA/ UNICEF/FNUAP/OMS sur la transmission mère-enfant du VIH, Genève, 11-13 octobre 2000. URL : at: http://www.who.int/ reproductive-health/pages_resources/listing_RTIs_STIs.htm.